## STE: STERIS plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.2% below STRENGTH zone (4.0-10.0%); PEG 1.74 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($250.46)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. The Truth About STERIS plc: Why Wall Street Is Quietly Obsessed (And Why You Should Care)**
- Source: AD HOC NEWS | 20260105T042022 | Bullish | Relevance: 100%
- STERIS plc (STE) is a healthcare giant specializing in infection prevention, sterilization, and endoscopy products crucial for hospitals. While not a social media sensation, its recurring revenue model and essential services make it a valuable long-term holding for investors seeking stability in the healthcare sector. The article advises that STE is a "cop" for patient investors valuing long-term growth over meme stock volatility.

**2. Asset Management One Co. Ltd. Buys 5,072 Shares of STERIS plc $STE**
- Source: MarketBeat | 20260106T080848 | Bullish | Relevance: 100%
- Asset Management One Co. Ltd. increased its holdings in STERIS plc by 5.4% during the third quarter, acquiring an additional 5,072 shares. Despite this institutional buying, STERIS saw significant insider selling, with two VPs selling off large portions of their stock. STERIS reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, and has a "Moderate Buy" analyst rating.

**3. Harvey Investment Co. LLC Raises Position in STERIS plc $STE**
- Source: MarketBeat | 20260105T132947 | Somewhat-Bullish | Relevance: 100%
- Harvey Investment Co. LLC increased its stake in STERIS plc (NYSE:STE) by 17.1% during the third quarter, making STERIS its 16th largest position and comprising approximately 2.5% of its holdings. STERIS reported strong Q3 earnings, beating analyst estimates with EPS of $2.47 and revenue of $1.46 billion, and maintains a consensus "Moderate Buy" rating with an average price target of $273.50. Despite insider selling, institutional investors own a significant 94.69% of the company's stock.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.75M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.4% (+0.4%)
- Blackrock Inc.: 8.9% (+1.3%)
- Massachusetts Financ: 4.9% (-7.7%)
- State Street Corpora: 4.4% (+4.0%)
- Morgan Stanley: 4.3% (+8.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.74 elevated, pricing in significant growth expectations. Forward P/E 23.4x stretched relative to 9% growth. Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.48). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.6B |
| Beta | 1.03 |
| 52W Range | $203.80 - $268.60 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.74 |
| Forward P/E | 23.4 |
| Current P/E | 25.5 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.4% to 1.2% (+1.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.8pp (needs >4.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. OFD pattern: +MUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.16% (CS: 51) | Neutral |
| RSI_14 | 57.7 | Neutral |
| MACD Histogram | 0.21 | Bullish |
| vs SMA20 | 1.020x | Above |
| vs SMA50 | 1.019x | Above |
| vs SMA200 | 1.080x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $260.00
- **Stop Loss:** $250.46 (3.7% risk)
- **Target:** $269.54 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 138
- **Position Value:** $35,880.00
- **Portfolio %:** 35.88%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-04 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.47 | +5.1% |
| 2025Q2 | $2.26 | $2.34 | +3.4% |
| 2025Q1 | $2.60 | $2.74 | +5.4% |
| 2024Q4 | $2.32 | $2.32 | -0.1% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*